Abstract: The present invention includes a method for analyzing tRNA-derived fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprising characterizing the identity of tRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying tRNA fragments. The invention also includes diagnosing, identifying or monitoring Parkinson's disease in a subject in need thereof by characterizing the identity of tRNA fragments.

Abstract: The present disclosure provides a method for assessing whether a uveal melanoma (UVM) patient has, or is at risk of developing a condition, the method comprising measuring the abundance of at least two isomiRs, and/or at least one tRNA derived fragment (tRF), in a biological sample obtained from the patient, and computing the difference in abundance of the at least two isomiRs and at least one tRF as an indication that the subject either has, or is at risk of developing, or is at a given stage of the condition.

Abstract: Disclosed herein are novel compositions, methods, and systems for determining whether a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest, or determining the tissue or cell provenance of a biological sample, based on expression level of one or more of the novel miRNA and isomiR sequences disclosed herein. The compositions, methods, and systems described herein can be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder, or determine the identity of the tissue or cell in a sample. In some embodiments, the compositions, methods, and systems described herein can be used to develop a treatment for the disease or disorder. For example, in some embodiments, the novel miRNAs can be used as therapeutics for treatment of a disease or disorder.

Abstract: Disclosed herein are novel compositions, methods, and systems for determining whether a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest, or determining the tissue or cell provenance of a biological sample, based on expression level of one or more of the novel miRNA and isomiR sequences disclosed herein. The compositions, methods, and systems described herein can be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder, or determine the identity of the tissue or cell in a sample. In some embodiments, the compositions, methods, and systems described herein can be used to develop a treatment for the disease or disorder. For example, in some embodiments, the novel miRNAs can be used as therapeutics for treatment of a disease or disorder.

Abstract: The present invention includes a method for analyzing tRNA-derived fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprising characterizing the identity of tRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying tRNA fragments. The invention also includes diagnosing, identifying or monitoring Parkinson's disease in a subject in need thereof by characterizing the identity of tRNA fragments.

Abstract: The present disclosure provides a method for assessing whether a uveal melanoma (UVM) patient has, or is at risk of developing a condition, the method comprising measuring the abundance of at least two isomiRs, and/or at least one tRNA derived fragment (tRF), in a biological sample obtained from the patient, and computing the difference in abundance of the at least two isomiRs and at least one tRF as an indication that the subject either has, or is at risk of developing, or is at a given stage of the condition.

Abstract: Disclosed herein are novel compositions, methods, and systems for determining whether a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest, or determining the tissue or cell provenance of a biological sample, based on expression level of one or more of the novel miRNA and isomiR sequences disclosed herein. The compositions, methods, and systems described herein can be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder, or determine the identity of the tissue or cell in a sample. In some embodiments, the compositions, methods, and systems described herein can be used to develop a treatment for the disease or disorder. For example, in some embodiments, the novel miRNAs can be used as therapeutics for treatment of a disease or disorder.